{
  "question_stem": {
    "en": "A 65-year-old woman comes to the clinic for a follow-up appointment. Medical history is notable for type 2 diabetes mellitus, hypertension, stable coronary artery disease, and heart failure with preserved ejection fraction. Blood pressure is 144/95 mm Hg. Physical examination shows no murmurs and the lungs are clear on auscultation. Fasting glucose is 122 mg/dL and hemoglobin A1c is 7.8%. The remainder of the laboratory results, including hepatic and renal markers, are within normal limits. She is prescribed canagliflozin. Which of the following potential complications should this patient be counseled on prior to initiation of this medication?",
    "zh": "一名65岁的女性前来诊所复诊。病史包括2型糖尿病、高血压、稳定的冠状动脉疾病和射血分数保留的心力衰竭。血压为144/95 mmHg。体格检查显示无杂音，听诊肺部清晰。空腹血糖为122 mg/dL，血红蛋白A1c为7.8%。其余实验室结果，包括肝脏和肾脏指标，均在正常范围内。她被处方了卡格列净。在开始使用这种药物之前，应该就以下哪种潜在并发症向该患者进行咨询？"
  },
  "question": {
    "en": "Which of the following potential complications should this patient be counseled on prior to initiation of this medication?",
    "zh": "在开始使用这种药物之前，应该就以下哪种潜在并发症向该患者进行咨询？"
  },
  "options": {
    "A": {
      "en": "Delayed gastric emptying",
      "zh": "胃排空延迟"
    },
    "B": {
      "en": "Fluid overload",
      "zh": "液体超负荷"
    },
    "C": {
      "en": "Hypoglycemia",
      "zh": "低血糖"
    },
    "D": {
      "en": "Lactic acidosis",
      "zh": "乳酸性酸中毒"
    },
    "E": {
      "en": "Vaginitis",
      "zh": "阴道炎"
    },
    "F": {
      "en": "Weight gain",
      "zh": "体重增加"
    }
  },
  "correct_answer": "E",
  "explanation": {
    "en": "Sodium-glucose cotransporter-2 (SGLT2) is a high-capacity transport protein that reabsorbs 90% of filtered glucose in the proximal tubule. SGLT2 inhibitors (eg, canagliflozin, dapagliflozin) are oral antidiabetic agents that decrease renal reabsorption of glucose and sodium, leading to urinary glucose loss and decreased blood glucose levels. The decreased reabsorption of sodium and glucose also induces osmotic diuresis and natriuresis, leading to a decrease in blood pressure and a lower rate of hospitalization for heart failure.\n\nHowever, the glycosuria induced by SGLT2 inhibitors creates a more favorable environment for pathogenic bacteria and fungi in the genitourinary tract and perineum. This leads to an increased risk for URINARY TRACT INFECTIONS (eg, pyelonephritis), GENITAL MYCOTIC INFECTIONS (eg, vaginitis), and NECROTIZING FASCIITIS of the perineum (ie, Fournier gangrene). Other adverse effects include hypovolemia, which can lead to orthostatic hypotension and acute kidney injury.\n\n(Choice A) Glucagon-like peptide-1 agonists (eg, exenatide, dulaglutide) lower blood glucose levels by increasing glucose-dependent insulin secretion and suppressing glucagon secretion. Adverse effects include delayed gastric emptying and a possible increased risk for pancreatitis.\n\n(Choice B) Thiazolidinediones (eg, pioglitazone) increase the reabsorption of sodium in the renal collecting tubule; this can lead to significant fluid retention, particularly in patients with heart failure. In contrast, SGLT2 inhibitors reduce fluid retention.\n\n(Choices C and F) Exogenous insulin and sulfonylureas (eg, glimepiride), which stimulate endogenous insulin secretion, can cause hypoglycemia and weight gain. SGLT2 inhibitors carry a low risk for hypoglycemia because the glucose-lowering effect is proportionate to the filtered glucose load. In addition, renal glucose wasting typically induces mild weight loss.\n\n(Choice D) Metformin inhibits hepatic gluconeogenesis, leading to the accumulation of lactate. Patients with decreased lactate clearance (eg, renal or hepatic dysfunction, congestive heart failure) can have excessive accumulation of lactate, leading to lactic acidosis. {{exhibit_1}}",
    "zh": "钠-葡萄糖协同转运蛋白2 (SGLT2) 是一种高容量转运蛋白，可在近端小管中重吸收90%的滤过葡萄糖。SGLT2抑制剂（例如，卡格列净、达格列净）是口服降糖药，可减少肾脏对葡萄糖和钠的重吸收，导致尿糖丢失和血糖水平降低。钠和葡萄糖重吸收的减少还会引起渗透性利尿和钠尿，从而导致血压降低和心力衰竭住院率降低。\n\n然而，SGLT2抑制剂引起的糖尿为泌尿生殖道和会阴部的病原菌和真菌创造了更有利的环境。这导致了尿路感染（例如，肾盂肾炎）、生殖器真菌感染（例如，阴道炎）和会阴坏死性筋膜炎（即，Fournier坏疽）的风险增加。其他不良反应包括血容量不足，这可能导致体位性低血压和急性肾损伤。\n\n（选项A）胰高血糖素样肽-1受体激动剂（例如，艾塞那肽、度拉糖肽）通过增加葡萄糖依赖性胰岛素分泌和抑制胰高血糖素分泌来降低血糖水平。不良反应包括胃排空延迟和可能增加的胰腺炎风险。\n\n（选项B）噻唑烷二酮类药物（例如，吡格列酮）增加肾集合管中钠的重吸收；这可能导致明显的液体潴留，尤其是在心力衰竭患者中。相比之下，SGLT2抑制剂可减少液体潴留。\n\n（选项C和F）外源性胰岛素和磺脲类药物（例如，格列美脲）可刺激内源性胰岛素分泌，引起低血糖和体重增加。SGLT2抑制剂引起低血糖的风险较低，因为降糖作用与滤过葡萄糖负荷成正比。此外，肾脏葡萄糖浪费通常会引起轻微的体重减轻。\n\n（选项D）二甲双胍抑制肝脏糖异生，导致乳酸蓄积。乳酸清除率降低的患者（例如，肾功能或肝功能障碍、充血性心力衰竭）可能过度蓄积乳酸，导致乳酸性酸中毒。{{exhibit_1}}"
  },
  "summary": {
    "en": "This question tests knowledge of the mechanism of action and side effects of SGLT2 inhibitors, specifically canagliflozin, in the management of type 2 diabetes mellitus.\n\nTo solve this question, recognize that SGLT2 inhibitors cause glycosuria, which increases the risk of genitourinary infections. Therefore, the patient should be counseled about the potential for vaginitis.",
    "zh": "本题考察了SGLT2抑制剂（特别是卡格列净）在2型糖尿病管理中的作用机制和副作用。\n\n要解决这个问题，需要认识到SGLT2抑制剂会引起糖尿，从而增加泌尿生殖道感染的风险。因此，应就阴道炎的可能性向患者进行咨询。"
  },
  "tags": "Type 2 diabetes mellitus; Canagliflozin; SGLT2 inhibitors; Vaginitis; Genitourinary infections; Endocrinology; Pharmacology",
  "category": "Endo",
  "question_id": "18956",
  "has_exhibits": true,
  "exhibit_count": 1,
  "exhibit_files": [
    "image1.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Endo 23\\18956",
  "extracted_at": "2025-11-05T14:03:38.160898",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T17:39:01.403139",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}